Spero Therapeutics, Inc. Annual Operating Income (Loss) in USD from 2015 to 2023

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
Spero Therapeutics, Inc. quarterly/annual Operating Income (Loss) history and growth rate from 2015 to 2023.
  • Spero Therapeutics, Inc. Operating Income (Loss) for the quarter ending June 30, 2024 was -$19.1M, a 47.9% decline year-over-year.
  • Spero Therapeutics, Inc. Operating Income (Loss) for the twelve months ending June 30, 2024 was $15.6M.
  • Spero Therapeutics, Inc. annual Operating Income (Loss) for 2023 was $21.5M.
  • Spero Therapeutics, Inc. annual Operating Income (Loss) for 2022 was -$42.2M, a 52% increase from 2021.
  • Spero Therapeutics, Inc. annual Operating Income (Loss) for 2021 was -$88M, a 11.2% decline from 2020.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Annual (USD)
Operating Income (Loss), YoY Annual Growth (%)
Period Value YoY Chg Change % Start Date End Date Report Filed
2023 $21.5M +$63.7M Jan 1, 2023 Dec 31, 2023 10-K 2024-03-13
2022 -$42.2M +$45.8M +52% Jan 1, 2022 Dec 31, 2022 10-K 2024-03-13
2021 -$88M -$8.86M -11.2% Jan 1, 2021 Dec 31, 2021 10-K 2023-03-30
2020 -$79.1M -$15.9M -25.1% Jan 1, 2020 Dec 31, 2020 10-K 2022-03-31
2019 -$63.2M -$20.4M -47.7% Jan 1, 2019 Dec 31, 2019 10-K 2021-03-11
2018 -$42.8M -$1.08M -2.58% Jan 1, 2018 Dec 31, 2018 10-K 2020-03-16
2017 -$41.7M -$8.51M -25.6% Jan 1, 2017 Dec 31, 2017 10-K 2019-03-14
2016 -$33.2M -$19.9M -149% Jan 1, 2016 Dec 31, 2016 10-K 2019-03-14
2015 -$13.3M Jan 1, 2015 Dec 31, 2015 10-K 2018-04-02
* An asterisk sign (*) next to the value indicates that the value is likely invalid.